Stockscreener 앱 받기
14.09
1.47%
-0.21
시간 외 거래:
14.05
-0.04
-0.28%
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO (NASDAQ:RGNX) Trading Down 3.8%Here's Why - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Behavioral Patterns of RGNX and Institutional Flows - Stock Traders Daily
REGENXBIO (NASDAQ:RGNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts By Investing.com - Investing.com Australia
Stifel Maintains REGENXBIO (RGNX) Buy Recommendation - Nasdaq
REGENXBIO (NASDAQ:RGNX) Shares Up 9.2%What's Next? - MarketBeat
What hedge fund activity signals for REGENXBIO Inc. stockCPI Data & Breakout Confirmation Trade Signals - DonanımHaber
Stifel Raises Price Target for Regenxbio (RGNX) to $45 | RGNX St - GuruFocus
Stifel raises Regenxbio stock price target to $45 on upcoming catalysts - Investing.com Nigeria
Decliners Report: How interest rate cuts could boost REGENXBIO Inc. stockQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Why REGENXBIO Inc. stock is recommended by analystsTreasury Yields & Detailed Earnings Play Alerts - DonanımHaber
Squarepoint Ops LLC Boosts Holdings in REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. stock reach Wall Street targetsForecast Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is REGENXBIO Inc. stock a smart buy before Fed meetingJuly 2025 Trends & Scalable Portfolio Growth Ideas - ulpravda.ru
How interest rate cuts could boost REGENXBIO Inc. stockPortfolio Gains Report & Consistent Return Investment Signals - Улправда
Is REGENXBIO Inc. stock a contrarian buy2025 Risk Factors & Fast Entry Momentum Trade Alerts - Улправда
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
Leerink Partners Maintains REGENXBIO (RGNX) Outperform Recommendation - Nasdaq
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity By Investing.com - Investing.com South Africa
Regenxbio (RGNX): Leerink Partners Raises Price Target to USD 20 - GuruFocus
Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity - Investing.com Nigeria
REGENXBIO (NASDAQ:RGNX) Reaches New 1-Year HighWhat's Next? - MarketBeat
RegenXBio’s gene therapy study for Hunter syndrome: A potential game-changer - MSN
RegenXBio’s Gene Therapy Study for Hunter Syndrome: A Potential Game-Changer - TipRanks
REGENXBIO (NASDAQ:RGNX) Stock Price Up 5.2%Time to Buy? - MarketBeat
(RGNX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
REGENXBIO (NASDAQ:RGNX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Wet Age-Related Macular Degeneration Market Growth - openPR.com
Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. $RGNX is 22NW LP's 5th Largest Position - MarketBeat
Regenxbio Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser
Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser
Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser
JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
How (RGNX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
26,773 Shares in REGENXBIO Inc. $RGNX Bought by Rockefeller Capital Management L.P. - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
0.23%
0.08%
자본화:
|
볼륨(24시간):